4D Molecular Therapeutics Says Interim Data From 4D-710 Phase 1 AEROW Trial For Cystic Fibrosis Lung Disease Shows Meaningful Lung Function Activity

Benzinga·12/17/2025 12:03:53

語音播報

Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2
Durable CFTR transgene expression within target therapeutic range with follow-up through at least 1 year
Data support 4D-710's potential to be a durable, redosable, variant-agnostic, disease-modifying treatment for people with cystic fibrosis lung disease with high unmet need